[Some problems due to the questionable indication for prescribing drugs].
Once a diagnosis has been done, prescribers must take into account the indications and method of use of a product before prescribing it. The indications are given in the Product License and noted in the Summary of Product Characteristics. The "RMO" informs on what would be dangerous or useless to prescribe. From now on French prescribers will have in addition to take into account indications admitted to reimbursement by the Sécurité Sociale that might be different from the Product License indications. Various problems will follow: Necessity to establish standardised and classified indications to be used by all. Necessity that this standardisation be at a European level. The indications given in the Product License must be in strict accordance with what is in the dictionary. Necessity for the prescribers to be continuously kept up to date on this dictionary. Risk of differences between general practice and hospital where there is no such opposability. This will affect therapeutic research in France. These problems must be examined as a whole.
Mangeot
J P
JP
Laboratoire Glaxo Wellcome, Paris.
D015400:Clinical Nursing Research; D011307:Drug Prescriptions; D005602:France; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D010819:Physician's Role; D012941:Social Responsibility; D012943:Social Security
D004364:Pharmaceutical Preparations
De quelques problèmes posés par l'opposabilité au médecin prescripteur des indications d'un médicament.